Document Detail


Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel.
MedLine Citation:
PMID:  23150876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Proteomic analyses of readily obtained human fluids (e.g., serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanoparticle-based multiplexed platform that has the potential for simultaneous read-out of large numbers of biomolecules. For this purpose, we have chosen pancreatic adenocarcinoma (PA) as a test bed for diagnosis and prognosis. PA is a devastating form of cancer in which an estimated 86% of diagnoses resulted in death in the United States in 2010. The high mortality rate is due, in part, to the asymptomatic development of the disease and the dearth of sensitive diagnostics available for early detection. One promising route lies in the development of a serum biomarker panel that can generate a signature unique to early stage PA. We describe the design and development of a proof-of-concept PA biomarker immunoassay array coupled with surface-enhanced Raman scattering (SERS) as a sensitive readout method.
Authors:
Jennifer H Granger; Michael C Granger; Matthew A Firpo; Sean J Mulvihill; Marc D Porter
Related Documents :
24263886 - Persons with disabilities, cancer screening and related factors.
23982466 - Association between cag repeat polymorphisms and the risk of prostate cancer: a meta-an...
7501536 - Outcomes that provide evidence of change in cancer pain management.
24300976 - Breast cancer survival and prognosis by screening history.
10382186 - Cervical cancer screening knowledge, behaviors, and beliefs of vietnamese women.
19137506 - No effect on survival of home psychosocial intervention in a randomized study of danish...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Analyst     Volume:  138     ISSN:  1364-5528     ISO Abbreviation:  Analyst     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-10     Completed Date:  2014-01-10     Revised Date:  2014-01-23    
Medline Journal Info:
Nlm Unique ID:  0372652     Medline TA:  Analyst     Country:  England    
Other Details:
Languages:  eng     Pagination:  410-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / diagnosis*
CA-19-9 Antigen / blood*
Gold / diagnostic use
Humans
Immunoassay
Matrix Metalloproteinase 7 / blood*
Metal Nanoparticles / diagnostic use
Pancreatic Neoplasms / diagnosis*
Prognosis
Proteomics
Spectrum Analysis, Raman*
Tumor Markers, Biological / blood
Grant Support
ID/Acronym/Agency:
P30CA042014/CA/NCI NIH HHS; R33 CA155586/CA/NCI NIH HHS; R33CA155586/CA/NCI NIH HHS; U01CA151650/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/CA-19-9 Antigen; 0/Tumor Markers, Biological; 7440-57-5/Gold; EC 3.4.24.23/MMP7 protein, human; EC 3.4.24.23/Matrix Metalloproteinase 7
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of cancer cells using a peptide nanotube-folic acid modified graphene electrode.
Next Document:  Asymmetric binary acid catalysis: chiral phosphoric acid as dual ligand and acid.